SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Associations between inflammatory biomarkers, symptoms, treatment toxicities and quality of life in people with advanced cancer receiving systemic anti-cancer treatments: a systematic review.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeExamine the quality of evidence relating to the association of routine inflammatory biomarkers neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) with symptoms, treatment toxicities, and quality of life (QoL) in people with advanced cancer.
methodsSearches were conducted in MEDLINE, Embase, CINAHL and the Cochrane database to identify studies that investigated associations between NLR, PLR and MLR with symptoms, toxicities and QoL in people with advanced cancer. The evidence was graded as good, fair or poor through the application of the National Institute of Health (NIH) quality assessment tool. A narrative approach was used for data synthesis.
resultsOf the 38 studies reviewed, NLR was the most frequently investigated biomarker. Thirteen studies found no association between NLR and symptoms or treatment toxicities. Of the 25 that did, five provided good quality evidence linking NLR to immune-related adverse events (irAEs), chemotherapy-related haematological toxicities and insufficient oral intake. However, NLR cut-off values varied across studies. Ten studies reported an association between PLR and symptoms or treatment toxicities whilst six studies found no associations; one study found no association with MLR and symptoms or treatment toxicities.
conclusionFurther research is needed to establish specific cut-off values of NLR to increase the utility of this biomarker in clinical practice. PLR and MLR warrant further investigation for association with symptoms, treatment toxicities and QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.